DOCSLIB.ORG

COMPLICATIONS of CIRRHOSIS Fluid Overload

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COMPLICATIONS of CIRRHOSIS Fluid Overload COMPLICATIONS OF CIRRHOSIS Fluid Overload: Fluid accumulates within the abdomen (ascites) and on the legs (pedal edema). This is due to both increased pressure inside the liver and because of the decreased production oF proteins (especially albumin) by the liver. Treatment is usually with medications to help lose the retained sodoum and water, or by draining the fluid with a needle. The higher the dietary salt intake, the higher the likelihood of developing fluid overload. Thus, patients with cirrhosis and fluid overload are often restricted to 2g/day oF dietary sodium. Part oF the pathophysiologic mechanism behind Fluid accumulation in the setting of cirrhosis is due to an alteration in the renin-angiotensin-aldosterone axis, and thereFore, medical treatment is targeted towards combatting this. Thus, patients with ascites or pedal edema are oFten started on spironolactone in combination with Furosemide. The spironolactone, an anti-mineralocorticoid agent, works well in patients with cirrhosis, but is required to be used in higher doses than in patients with heart Failure. As well, the combination oF both a loop diuretic (Furosemide) and anti-aldosterone (spironolactone) is more eFFicacious than either diuretic alone. Thus, these 2 medications are used together, with 100mg oF Spironolactone being used with 40 mg oF Lasix. The two drugs are then titrated up together to maintain this ratio, barring any complications or electrolyte abnormalities. Hepatic encephalopathy: Normally, the liver detoxiFies the various toxins that are both produced by the body and ingested (usually as medications). In the setting oF liver Failure, or cirrhosis, the liver is no longer able to do this, and the toxins build up in the bloodstream and cross over into the liver. Patients with encephalopathy can have problems with decreased concentration, excessive Fatigue (sleeping a lot), conFusion, or even coma. One oF these toxins is ammonia. Hepatic encephalopathy can be precipated by medications (any sedating medications, such as narcotics, benzodiazepines, or neuroleptics), infections (especially spontaneous bacterial peritonitis, UTI, or URTI), constipation, renal Failure, or electrolyte abnormalities. Treatment is aimed at treating the precipitating cause and simultaneous removal oF the ammonia. Lactulose serves to draw ammonia From the bloodstream into the colon, and then stimulates colonic motility to expel the ammonia From the body. Thus, lactulose acts as more than a simple laxative. Variceal Bleeding: As the amount oF scarring in the liver increases, it becomes more diFFicult For the blood to Flow through the liver, and it starts looking For other, lower resistance routes through which to flow. This leads to the development oF varices, both in the esophagus and stomach, as well as elsewhere. As these veins get bigger, they are at risk For bursting and bleeding. IF this occurs, it can be catastrophic, and may lead to death. In order to prevent this From occurring, there are 2 methods oF treatment. The First is to decrease the pressure in the portal system, which can be achieved through the administration oF non-selective beta-blockers such as Nadolol or Carvedilol. Another method oF variceal treatment is through endoscopic ligation or gluing oF the varices. Which oF these methods is used to control the varices is based on the severity of the patient’s liver disease, the size of the esophageal varices, and whether there are any high risk Features seen endoscopically to indicate whether the varices are at higher risk for rupture and bleeding. Once a patient has been banded, they are then placed into a banding program, where they are brought back to the endoscopy suite For banding every 4 weeks until the varices have been completely eradicated. Jaundice: As the liver becomes less and less able to Function, patients may start to develop yellowing of either the skin or the eyes, which is due to the build-up of bilirubin in the blood (bilirubin is normally excreted into the intestines by the liver via the bile ducts, and From there, into the stool). Although this can be seen in acute hepatitis, in patients with pre-existing liver disease, the development oF jaundice can indicate an acute flare oF their underlying disease, or worsening liver function. Liver Cancer: Having cirrhosis is a risk for developing liver cancer (hepatocellular carcinoma, or HCC). IF this develops, there are a number oF diFFerent options For treatment oF the cancer, based on how well your liver is Functioning, and its size. Please reFer to the “Liver Tumour” section For Further inFormation. All patients with cirrhosis should undergo a screening program with an abdominal ultrasound every 6 months as part oF HCC surveillance. .
Load more

Recommended publications
  • Inflammatory Bowel Disease Irritable Bowel Syndrome
    Inflammatory Bowel Disease and Irritable Bowel Syndrome Similarities and Differences 2 www.ccfa.org IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 Important Differences Between IBD and IBS Many diseases and conditions can affect the gastrointestinal (GI) tract, which is part of the digestive system and includes the esophagus, stomach, small intestine and large intestine. These diseases and conditions include inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 www.ccfa.org 3 Inflammatory bowel diseases are a group of inflammatory conditions in which the body’s own immune system attacks parts of the digestive system. Inflammatory Bowel Disease Inflammatory bowel diseases are a group of inflamma- Causes tory conditions in which the body’s own immune system attacks parts of the digestive system. The two most com- The exact cause of IBD remains unknown. Researchers mon inflammatory bowel diseases are Crohn’s disease believe that a combination of four factors lead to IBD: a (CD) and ulcerative colitis (UC). IBD affects as many as 1.4 genetic component, an environmental trigger, an imbal- million Americans, most of whom are diagnosed before ance of intestinal bacteria and an inappropriate reaction age 35. There is no cure for IBD but there are treatments to from the immune system. Immune cells normally protect reduce and control the symptoms of the disease. the body from infection, but in people with IBD, the immune system mistakes harmless substances in the CD and UC cause chronic inflammation of the GI tract. CD intestine for foreign substances and launches an attack, can affect any part of the GI tract, but frequently affects the resulting in inflammation.
    [Show full text]
  • Evaluation of Abnormal Liver Chemistries
    ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Paul Y. Kwo, MD, FACG, FAASLD1, Stanley M. Cohen, MD, FACG, FAASLD2, and Joseph K. Lim, MD, FACG, FAASLD3 1Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA; 2Digestive Health Institute, University Hospitals Cleveland Medical Center and Division of Gastroenterology and Liver Disease, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; 3Yale Viral Hepatitis Program, Yale University School of Medicine, New Haven, Connecticut, USA. Am J Gastroenterol 2017; 112:18–35; doi:10.1038/ajg.2016.517; published online 20 December 2016 Abstract Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cholestasis. Multiple studies have demonstrated that the presence of an elevated ALT has been associated with increased liver-related mortality. A true healthy normal ALT level ranges from 29 to 33 IU/l for males, 19 to 25 IU/l for females and levels above this should be assessed. The degree of elevation of ALT and or AST in the clinical setting helps guide the evaluation.
    [Show full text]
  • A Drug-Induced Cholestatic Pattern
    Review articles Hepatotoxicity: A Drug-Induced Cholestatic Pattern Laura Morales M.,1 Natalia Vélez L.,1 Octavio Germán Muñoz M., MD.2 1 Medical Student in the Faculty of Medicine and Abstract the Gastrohepatology Group at the Universidad de Antioquia in Medellín, Colombia Although drug induced liver disease is a rare condition, it explains 40% to 50% of all cases of acute liver 2 Internist and Hepatologist at the Hospital Pablo failure. In 20% to 40% of the cases, the pattern is cholestatic and is caused by inhibition of the transporters Tobon Uribe and in the Gastrohepatology Group at that regulate bile synthesis. This reduction in activity is directly or indirectly mediated by drugs and their me- the Universidad de Antioquia in Medellín, Colombia tabolites and/or by genetic polymorphisms and other risk factors of the patient. Its manifestations range from ......................................... biochemical alterations in the absence of symptoms to acute liver failure and chronic liver damage. Received: 30-01-15 Although there is no absolute test or marker for diagnosis of this disease, scales and algorithms have Accepted: 26-01-16 been developed to assess the likelihood of cholestatic drug induced liver disease. Other types of evidence are not routinely used because of their complexity and cost. Diagnosis is primarily based on exclusion using circumstantial evidence. Cholestatic drug induced liver disease has better overall survival rates than other patters, but there are higher risks of developing chronic liver disease. In most cases, the patient’s condition improves when the drug responsible for the damage is removed. Hemodialysis and transplantation should be considered only for selected cases.
    [Show full text]
  • Acute Liver Failure J G O’Grady
    148 Postgrad Med J: first published as 10.1136/pgmj.2004.026005 on 4 March 2005. Downloaded from REVIEW Acute liver failure J G O’Grady ............................................................................................................................... Postgrad Med J 2005;81:148–154. doi: 10.1136/pgmj.2004.026005 Acute liver failure is a complex multisystemic illness that account for most cases, but a significant number of patients have no definable cause and are evolves quickly after a catastrophic insult to the liver classified as seronegative or of being of indeter- leading to the development of encephalopathy. The minate aetiology. Paracetamol is the commonest underlying aetiology and the pace of progression strongly cause in the UK and USA.2 Idiosyncratic reac- tions comprise another important group. influence the clinical course. The commonest causes are paracetamol, idiosyncratic drug reactions, hepatitis B, and Viral seronegative hepatitis. The optimal care is multidisciplinary ALF is an uncommon complication of viral and up to half of the cases receive liver transplants, with hepatitis, occurring in 0.2%–4% of cases depend- ing on the underlying aetiology.3 The risk is survival rates around 75%–90%. Artificial liver support lowest with hepatitis A, but it increases with the devices remain unproven in efficacy in acute liver failure. age at time of exposure. Hepatitis B can be associated with ALF through a number of ........................................................................... scenarios (table 2). The commonest are de novo infection and spontaneous surges in viral repli- cation, while the incidence of the delta virus cute liver failure (ALF) is a complex infection seems to be decreasing rapidly. multisystemic illness that evolves after a Vaccination should reduce the incidence of Acatastrophic insult to the liver manifesting hepatitis A and B, while antiviral drugs should in the development of a coagulopathy and ameliorate replication of hepatitis B.
    [Show full text]
  • Constipation
    Constipation Caris Diagnostics Health Improvement Series What is constipation? Constipation means that a person has three bowel movements or fewer in a week. The stool is hard and dry. Sometimes it is painful to pass. You may feel‘draggy’and full. Some people think they should have a bowel movement every day. That is not really true. There is no‘right’number of bowel movements. Each person's body finds its own normal number of bowel movements. It depends on the food you eat, how much you exercise, and other things. At one time or another, almost everyone gets constipated. In most cases, it lasts for a short time and is not serious. When you understand what causes constipation, you can take steps to prevent it. What can I do about constipation? Changing what you 4. Allow yourself enough time to have a bowel movement. eat and drink and how much you exercise will help re- Sometimes we feel so hurried that we don't pay atten- lieve and prevent constipation. Here are some steps you tion to our body's needs. Make sure you don't ignore the can take. urge to have a bowel movement. 1. Eat more fiber. Fiber helps form soft, bulky stool. It 5. Use laxatives only if a doctor says you should. is found in many vegetables, fruits, and grains. Be sure Laxatives are medicines that will make you pass a stool. to add fiber a little at a time, so your body gets used to Most people who are mildly constipated do not need it slowly.
    [Show full text]
  • Hepatitis A, B, and C: Learn the Differences
    Hepatitis A, B, and C: Learn the Differences Hepatitis A Hepatitis B Hepatitis C caused by the hepatitis A virus (HAV) caused by the hepatitis B virus (HBV) caused by the hepatitis C virus (HCV) HAV is found in the feces (poop) of people with hepa- HBV is found in blood and certain body fluids. The virus is spread HCV is found in blood and certain body fluids. The titis A and is usually spread by close personal contact when blood or body fluid from an infected person enters the body virus is spread when blood or body fluid from an HCV- (including sex or living in the same household). It of a person who is not immune. HBV is spread through having infected person enters another person’s body. HCV can also be spread by eating food or drinking water unprotected sex with an infected person, sharing needles or is spread through sharing needles or “works” when contaminated with HAV. “works” when shooting drugs, exposure to needlesticks or sharps shooting drugs, through exposure to needlesticks on the job, or from an infected mother to her baby during birth. or sharps on the job, or sometimes from an infected How is it spread? Exposure to infected blood in ANY situation can be a risk for mother to her baby during birth. It is possible to trans- transmission. mit HCV during sex, but it is not common. • People who wish to be protected from HAV infection • All infants, children, and teens ages 0 through 18 years There is no vaccine to prevent HCV.
    [Show full text]
  • Diagnosis and Management of Primary Biliary Cholangitis Ticle
    REVIEW ArtICLE 1 see related editorial on page x Diagnosis and Management of Primary Biliary Cholangitis TICLE R Zobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD1, David Bernstein, MD, FAASLD, FACG, AGAF, FACP2, Mitchell L. Shifman, MD3, Paul Kwo, MD4, W. Ray Kim, MD5, Kris V. Kowdley, MD6 and Ira M. Jacobson, MD7 Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune disease with a variable progressive course. PBC can cause debilitating symptoms including fatigue and pruritus and, if left untreated, is associated with a high risk of cirrhosis and related complications, liver failure, and death. Recent changes to the PBC landscape include a REVIEW A name change, updated guidelines for diagnosis and treatment as well as new treatment options that have recently become available. Practicing clinicians face many unanswered questions when managing PBC. To assist these healthcare providers in managing patients with PBC, the American College of Gastroenterology (ACG) Institute for Clinical Research & Education, in collaboration with the Chronic Liver Disease Foundation (CLDF), organized a panel of experts to evaluate and summarize the most current and relevant peer-reviewed literature regarding PBC. This, combined with the extensive experience and clinical expertise of this expert panel, led to the formation of this clinical guidance on the diagnosis and management of PBC. Am J Gastroenterol https://doi.org/10.1038/s41395-018-0390-3 INTRODUCTION addition, diagnosis and treatment guidelines are changing and a Primary biliary cholangitis (PBC) is a chronic, cholestatic, auto- number of guidelines have been updated [4, 5]. immune disease with a progressive course that may extend over Because of important changes in the PBC landscape, and a num- many decades.
    [Show full text]
  • Food and Ibd Condition Your Guide Introduction
    CROHN’S & COLITIS UK SUPPORTING YOU TO MANAGE YOUR FOOD AND IBD CONDITION YOUR GUIDE INTRODUCTION ABOUT THIS BOOKLET If you have Ulcerative Colitis (UC) or Crohn’s Disease (the two main forms of Inflammatory Bowel Disease - IBD) you may wonder whether food or diet plays a role in causing your illness or treating your symptoms. This booklet looks at some of the most frequently asked questions about food and IBD, and provides background information on digestion and healthy eating for people with IBD. We hope you will find it helpful. All our publications are research based and produced in consultation with patients, medical advisers and other health or associated professionals. However, they are prepared as general information and are not intended to replace specific advice from your own doctor or any other professional. Crohn’s and Colitis UK does not endorse or recommend any products mentioned. If you would like more information about the sources of evidence on which this booklet is based, or details of any conflicts of interest, or if you have any feedback on our publications, please visit our website. About Crohn’s and Colitis UK We are a national charity established in 1979. Our aim is to improve life for anyone affected by Inflammatory Bowel Diseases. We have over 28,000 members and 50 local groups throughout the UK. Membership costs from £15 per year with concessionary rates for anyone experiencing financial hardship or on a low income. This publication is available free of charge, but we © Crohn’s and Colitis UK would not be able to do this without our supporters 2015 and 2016 and members.
    [Show full text]
  • Therapeutic Enema for Intussusception
    Therapeutic Enema for Intussusception Therapeutic enema is used to help identify and diagnose intussusception, a serious disorder in which one part of the intestine slides into another in a telescoping manner and causes inflammation and an obstruction. Intussusception often occurs at the junction of the small and large intestine and most commonly occurs in children three to 24 months of age. A therapeutic enema using air or a contrast material solution may be performed to create pressure within the intestine and "un-telescope" the intussusception while relieving the obstruction. This exam is usually performed on an emergency basis. Tell your doctor about your child's recent illnesses, medical conditions, medications and allergies, especially to barium or iodinated contrast materials. Your child may be asked to wear a gown and remove any objects that might interfere with the x-ray images. An ultrasound may be performed to help confirm the diagnosis. What is a Therapeutic Enema for Intussusception? What is intussusception? Intussusception is a serious disorder in which one part of the intestine slides into another part of the intestine, similar to a collapsing telescope. The intestine becomes inflamed and swollen and can cause an obstruction or blockage. Symptoms can include severe abdominal pain, fever, vomiting or abnormal stools. Intussusception may occur anywhere along the gastrointestinal tract; however, it often occurs at the junction of the small and large intestine. The condition most commonly occurs in children three months to 24 months of age. Intussusception is a medical/surgical emergency. If your child has some or all of the symptoms of intussusception, you should call your physician or an emergency medical professional immediately.
    [Show full text]
  • Guideline for the Evaluation of Cholestatic Jaundice
    CLINICAL GUIDELINES Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition ÃRima Fawaz, yUlrich Baumann, zUdeme Ekong, §Bjo¨rn Fischler, jjNedim Hadzic, ôCara L. Mack, #Vale´rie A. McLin, ÃÃJean P. Molleston, yyEzequiel Neimark, zzVicky L. Ng, and §§Saul J. Karpen ABSTRACT Cholestatic jaundice in infancy affects approximately 1 in every 2500 term PREAMBLE infants and is infrequently recognized by primary providers in the setting of holestatic jaundice in infancy is an uncommon but poten- physiologic jaundice. Cholestatic jaundice is always pathologic and indicates tially serious problem that indicates hepatobiliary dysfunc- hepatobiliary dysfunction. Early detection by the primary care physician and tion.C Early detection of cholestatic jaundice by the primary care timely referrals to the pediatric gastroenterologist/hepatologist are important physician and timely, accurate diagnosis by the pediatric gastro- contributors to optimal treatment and prognosis. The most common causes of enterologist are important for successful treatment and an optimal cholestatic jaundice in the first months of life are biliary atresia (25%–40%) prognosis. The Cholestasis Guideline Committee consisted of 11 followed by an expanding list of monogenic disorders (25%), along with many members of 2 professional societies: the North American Society unknown or multifactorial (eg, parenteral nutrition-related) causes, each of for Gastroenterology, Hepatology and Nutrition, and the European which may have time-sensitive and distinct treatment plans. Thus, these Society for Gastroenterology, Hepatology and Nutrition. This guidelines can have an essential role for the evaluation of neonatal cholestasis committee has responded to a need in pediatrics and developed to optimize care.
    [Show full text]
  • Sudden (Acute) Liver Failure
    Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Sudden (Acute) Liver Failure Basics OVERVIEW • Sudden (acute) damage to the liver tissue that is so severe that the liver is unable to function properly and meet the needs of the body • Sudden (acute) loss of more than 75% of functional liver tissue; occurs primarily because of sudden (acute), massive death of liver tissue (known as “hepatic necrosis”), which has a catastrophic effect on multiple organs in a previously healthy pet; may rapidly lead to death • The liver is the largest gland in the body; it has many functions, including production of bile (a fluid substance involved in digestion of fats); production of albumin (a protein in the plasma of the blood); and detoxification of drugs and other chemicals (such as ammonia) in the body SIGNALMENT/DESCRIPTION OF PET Species • Dogs • Cats • More common in dogs than in cats Breed Predilections • Breeds that appear to have increased likelihood of having long-term inflammation of the liver (known as “chronic hepatitis”) as compared to other breeds may have higher risk of sudden (acute) liver failure SIGNS/OBSERVED CHANGES IN THE PET • Sudden (acute) onset • Sluggishness (lethargy) • Decreased appetite (known as “inappetence”) • Vomiting • Small intestinal diarrhea—may be bloody • Increased thirst (known as “polydipsia”) and increased urination (known as “polyuria”) • Enlargement of the liver (known as “hepatomegaly”), with tenderness of the liver on feeling the abdomen
    [Show full text]
  • COVID-19 and Liver Cirrhosis Important Information for Patients and Their Families
    COVID-19 and Liver Cirrhosis Important Information for Patients and Their Families The American Association for the Study of Liver Diseases (AASLD) is committed to helping you understand coronavirus disease 2019 (COVID-19) infection and prevention in people with liver cirrhosis. What We Know Our understanding of COVID-19 in people with liver cirrhosis is evolving. When making decisions related to COVID-19 infections or prevention, having up-to-date information is critical. • Symptoms of COVID-19 infection include any of the following: fever, chills, drowsiness, cough, congestion or runny nose, difficulty breathing, fatigue, body aches, headache, sore throat, abdominal pain, nausea, vomiting, diarrhea, and loss of sense of taste or smell. • People with underlying cirrhosis of the liver are at a higher risk of developing severe COVID-19 illness and/or more problems from their existing liver disease if they get a COVID-19 infection, with prolonged hospitalization and increased mortality. These patients need to take careful precautions to avoid COVID-19 infection. COVID-19 may affect the processes and procedures for screening, diagnosis, and treatment of liver cirrhosis. • Cirrhosis, or scarring of the liver, can be caused by many chronic liver diseases, including viral hepatitis, as well as excessive alcohol intake, obesity, diabetes, diseases of the bile ducts, and a variety of toxic, metabolic, or other inherited diseases. • Most people with liver disease are asymptomatic. Complications, such as yellowing of the skin and eyes from jaundice, internal bleeding (varices), mental confusion (hepatic encephalopathy), and/or swollen belly from ascites, may take years to develop, so patients are often unaware of the severity of their condition and the slow, progressive damage.
    [Show full text]